Clinical trial

A Study to Test Different Doses of BI 1569912 in People With Depression

NCT06558344

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2024-10-01

PhasePHASE2

Study timeline

Study start (actual)2024-10-01Date precision: day

Registry last updated2026-05-22

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Depressive Disorder, Majorunresolved

Interventions

5 mg BI 1569912DRUG

Placebo matching BI 1569912DRUG

10 mg BI 1569912DRUG

20 mg of BI 1569912DRUG

Sponsors & collaborators

Boehringer Ingelheimlead sponsor

Mapped research locations

MiamiFlorida, United States2 New YorkNew York, United States1 BostonMassachusetts, United States1 DallasTexas, United States1 BaltimoreMaryland, United States1 AtlantaGeorgia, United States1 San DiegoCalifornia, United States1 JacksonvilleFlorida, United States1 OrlandoFlorida, United States1 Oklahoma CityOklahoma, United States1 The BronxNew York, United States1 MemphisTennessee, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06558344 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.